BiotechTube
AMYRA Biotech

AMYRA Biotech

Zug, Switzerland· Est.
amyra.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

AMYRA Biotech is a private, pre-clinical stage biotech developing a novel enzyme therapy for celiac disease and non-celiac gluten sensitivity. Its core technology, the BBEST (Bread and Breakfast Enzyme Support Therapy) platform, aims to degrade immunogenic gluten peptides in the stomach before they trigger an immune response. The company is positioned to address a significant unmet medical need in a large and growing market, with its lead program advancing through preclinical development. As a private entity, its financial runway and future development milestones are likely dependent on securing further investment or partnerships.

GastroenterologyAutoimmune Diseases

Technology Platform

BBEST (Bread and Breakfast Enzyme Support Therapy) platform for discovering and engineering novel gluten-degrading enzymes that function in the acidic stomach environment.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

Addressing a large, underserved market of millions with celiac disease and gluten sensitivity where the only current treatment is a strict, lifelong diet.
A successful enzyme therapy could command premium pricing as a first-in-class pharmaceutical intervention and potentially expand into broader food intolerance markets.

Risk Factors

High scientific risk in developing an enzyme effective in the complex human stomach environment.
Financial risk as a pre-revenue company dependent on funding milestones.
Future competition from other companies developing enzymatic, vaccine, or immunomodulatory approaches for celiac disease.

Competitive Landscape

The pharmacological treatment space for celiac disease is nascent but evolving. Competitors include companies like ImmunogenX (latiglutenase), Takeda (TAK-062), and others exploring different therapeutic modalities. The primary competition remains the gluten-free food industry, but no drug is currently approved.

More companies in Biologics / Biosimilars →More companies in Switzerland →